MOTIF BIO PLC/S (NASDAQ:MTFB) Stock Price Down 6.3%

MOTIF BIO PLC/S (NASDAQ:MTFB) shares were down 6.3% during trading on Friday . The company traded as low as $0.13 and last traded at $0.15, approximately 584,317 shares changed hands during trading. An increase of 59% from the average daily volume of 366,707 shares. The stock had previously closed at $0.16.

A number of research analysts have commented on MTFB shares. Zacks Investment Research upgraded shares of MOTIF BIO PLC/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 8th. Northland Securities set a $5.00 price target on shares of MOTIF BIO PLC/S and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, ValuEngine upgraded shares of MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

The business’s 50 day simple moving average is $0.29 and its 200 day simple moving average is $0.89. The stock has a market cap of $2.67 million, a P/E ratio of -2.14 and a beta of -0.12.

An institutional investor recently raised its position in MOTIF BIO PLC/S stock. Susquehanna International Group LLP lifted its position in shares of MOTIF BIO PLC/S (NASDAQ:MTFB) by 207.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,657 shares of the company’s stock after purchasing an additional 26,740 shares during the quarter. Susquehanna International Group LLP owned 0.27% of MOTIF BIO PLC/S worth $26,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.58% of the company’s stock.

MOTIF BIO PLC/S Company Profile (NASDAQ:MTFB)

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.

Featured Story: What is operating income?

Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit